TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03838289

Intervention type: RADIATION
Intervention: multimodal magnetic resonance imaging or computed tomography
Description: multimodal magnetic resonance imaging including T1 Flair,T2 Flair, magnetic resonance angiography (MRA), perfusion-weighted imaging (PWI), diffusion-weighted imaging (DWI), enhanced gradient echo T2 star weighted angiography (ESWAN); multimodal computed tomography including non-contrast CT, volume perfusion CT

Intervention type: RADIATION
Intervention: multimodal magnetic resonance imaging or computed tomography
Description: multimodal magnetic resonance imaging including T1 Flair,T2 Flair, magnetic resonance angiography (MRA), perfusion-weighted imaging (PWI), diffusion-weighted imaging (DWI), enhanced gradient echo T2 star weighted angiography (ESWAN); multimodal computed tomography including non-contrast CT, volume perfusion CT
Study: NCT02815332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPX-01 1% Minocycline Topical Gel
Description: Approximately 1 gram applied once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPX-01 2% Minocycline Topical Gel
Description: Approximately 1 gram applied once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BPX-01 Vehicle Topical Gel
Description: Approximately 1 gram applied once daily for 12 weeks
Study: NCT00846248

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chromium
Description: We will enroll non-obese, non-diabetic subjects with insulin resistance in a 16 week treatment program with 500 μg of chromium picolinate twice daily. Insulin action will be determined by insulin clamp and OGTT using deuterated glucose both before and after treatment. Subjects will be compared to a placebo-treated group.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Chromium
Description: We will enroll non-obese, non-diabetic subjects with insulin resistance in a 16 week treatment program with 500 μg of chromium picolinate twice daily. Insulin action will be determined by insulin clamp and OGTT using deuterated glucose both before and after treatment. Subjects will be compared to a placebo-treated group.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: We will enroll non-obese, non-diabetic subjects with insulin resistance in a 16 week treatment program with 500 μg of chromium picolinate twice daily. Insulin action will be determined by insulin clamp and OGTT using deuterated glucose both before and after treatment. Subjects will be compared to a placebo-treated group.
Study: NCT02215395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NES/EE CVR
Description: Concurrent administration of vaginal antimycotic medication (Miconazole Nitrate) on the pharmacokinetics of Nestorone (NES) and ethinyl estradiol (EE) delivered by a contraceptive vaginal ring (CVR)
Study: NCT02951208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Active anodal tDCS over the left DLPFC, administered for 30 minutes, three times per week for four weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active VR Motivation Training
Description: Active computerized treatment with a virtual reality-based motivation training program, administered for 60 minutes, three times per week for four weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham anodal tDCS over the left DLPFC, administered for 30 minutes, three times per week for four weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham VR Motivation Training
Description: Sham computerized training in a virtual reality-based environment, administered for 60 minutes, three times per week for four weeks.
Study: NCT02693470

Intervention type: DRUG
Group type: OTHER
Intervention: Ustekinumab
Description: 50 patients with severe psoriasis received ustekinumab 45mg at 0 and 1 month. There were 50 healthy controls. The levels of circulating CD31 and CD41a positive microparticles are measured. In patients with psoriasis, the investigators measure microparticles in the baseline and 4 months after ustekinumab. For control group, the investigators measure microparticles in the baseline.
Study: NCT03416426

Intervention type: DEVICE
Intervention: Amplatzer® PFO occluder or Gore® Septal Occluder
Description: The closure procedure was performed under general anesthesia. After achieving femoral venous access, the PFO was crossed with a 5F multipurpose catheter, which was advanced into the left upper pulmonary vein and then exchanged over a 0.035 inch J-tipped stiff guidewire for an 8F or 9F guiding sheath. Procedural anticoagulation was initiated with 5000 units of intravenous heparin. After then additional heparin was administrated throughout procedure to maintain an activated clotting time of ≥250 seconds. Device size was selected based on TEE measurements of the distance between the PFO and the aortic root.
Study: NCT01842919

Intervention type: OTHER
Group type: OTHER
Intervention: Kinesthetics tests

Intervention type: OTHER
Group type: OTHER
Intervention: Kinesthetics tests
Study: NCT00813150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Type=exact number, number=20, unit=mg, form=tablet, route=oral. The patients will receive 20 mg of dexamethasone on days 1+2,4+5,8+9,11+12 for 21 days for 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Type=exact number, number=20, unit=mg, form=tablet, route=oral. The patients will receive 20 mg of dexamethasone on days 1+2,4+5,8+9,11+12 for 21 days for 8 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Type=exact number, number=1.3, unit=mg, form=injection, route=intravenous. The patients will receive 1.3mg/m2 on days 1,4,8,11 for 21 days for 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Type=exact number, number=1.3, unit=mg, form=injection, route=intravenous. The patients will receive 1.3mg/m2 on days 1,4,8,11 for 21 days for 8 cycles.
Study: NCT01842919

Intervention type: OTHER
Group type: OTHER
Intervention: Kinesthetics tests

Intervention type: OTHER
Group type: OTHER
Intervention: Psychological questionnaires
Study: NCT00813150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Type=exact number, number=50, unit=mg, form=tablet, route=oral. The patients will receive 50 mg of cyclophosphamide once daily continuously from cycle 1 to 8.
Study: NCT01405339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucosal Atomization Device (MAD)
Description: The use of pulmicort via MAD once a day for a total of 30 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide via Nasal Syringe
Description: The use of budesonide via Sinus Irrigation Bottle will be once a day for 30 days.
Study: NCT03620305

Intervention type: OTHER
Intervention: Description of treatment of septic pseudarthrosis
Description: description of chirurgical 2 steps management of septic pseudarthrosis
Study: NCT01408381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells
Description: Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x108, 5x108 and 1x109 low, intermediate and high dose in the arms respectively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells
Description: Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x108, 5x108 and 1x109 low, intermediate and high dose in the arms respectively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells
Description: Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x108, 5x108 and 1x109 low, intermediate and high dose in the arms respectively.
Study: NCT03563352

Intervention type: OTHER
Intervention: Interview
Description: Attend an interview

Intervention type: OTHER
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT03484663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: central venous catheter (small catheter drainage)
Description: Insertion central venous catheter ( small catheter drainage ) after uniport vats to decrease hospital stay and to easy drainage after procedure
Study: NCT01475708

Intervention type: DRUG
Intervention: Doxycycline
Description: 100 mg PO bid, 14 days

Intervention type: DRUG
Intervention: Doxycycline
Description: 100 mg PO bid, 14 days

Intervention type: DRUG
Intervention: Doxycycline
Description: 100 mg PO bid, 14 days
Study: NCT04891146

Intervention type: OTHER
Intervention: Systemic inflammatory immmune index
Description: Systemic Inflammatory Immune index calculated from platelet, neutrophil and lymphocyte count

Intervention type: OTHER
Intervention: Systemic inflammatory immmune index
Description: Systemic Inflammatory Immune index calculated from platelet, neutrophil and lymphocyte count
Study: NCT01579422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social cognitive training
Description: social cognitive training, 8-10 sessions
Study: NCT02461069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimethyl fumarate
Description: Dimethyl fumarate (Tecfidera®) treatment is initiated by daily administration of 120 mg Tecfidera® p.o. in the morning in week 0. At week 1, the dose is increased to 120 mg Tecfidera® p.o. twice daily, split into a morning and an evening dose. At week 2, the daily dose is further increased to 240 mg Tecfidera® p.o. in the morning and 120 mg Tecfidera® p.o. in the evening. Finally at week 3, the dose will be increased to the final daily dose of 240 mg Tecfidera® p.o. in the morning and 240 mg Tecfidera® p.o. in the evening and maintained throughout the study.
Study: NCT00415818

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-MUC1-IL2
Description: MVA-MUC1-IL2:~Dose of 10exp8 plaque forming units (pfu).~Chemotherapy:~Arm 1 and Arm 2 Intravenous CT: cisplatin (75mg/m² at Day 1) and gemcitabine (1250mg/m² at Days 1 and 8) every 3 weeks, for up to six cycles or until progressive disease, whichever occurred first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1st line Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1st line Chemotherapy
Study: NCT03018080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV (in the vein) on day 1 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV (in the vein) on day 1 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV (in the vein) on days 1 and 8 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV (in the vein) on days 1 and 8 of a 21 day cycle
Study: NCT04543149

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometric immunophenotyping
Description: To evaluate T cell subsets and monocyte

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometric immunophenotyping
Description: To evaluate T cell subsets and monocyte
Study: NCT03021083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IONSYS Patch
Description: Patient controlled transdermal fentanyl patch, IONSYS, applied to patient in place of a PCA.
Study: NCT04105296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EKSO+ES
Description: 6 months of exoskeleton training with epidural stimulation.
Study: NCT00934336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic and preventive strategies
Description: These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic and preventive strategies
Description: These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
Study: NCT04332081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen therapy (HBOT)
Description: The patient will receive 90 minutes of hyperbaric oxygen at 2.0 ATA with or without airbreaks per the hyperbaric physician. Upon completion of the treatment the patient will then return to the medial unit and continue all standard of care. Additional treatments (up to 5) can be given if warranted and agreed upon by the patient and all members of the team caring for the patient.
Study: NCT01842919

Intervention type: OTHER
Group type: OTHER
Intervention: Psychological questionnaires

Intervention type: OTHER
Group type: OTHER
Intervention: structural Magnetic ResonanceImaging (MRI)

Intervention type: OTHER
Group type: OTHER
Intervention: structural Magnetic ResonanceImaging (MRI)
Study: NCT00624936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vidaza
Description: Vidaza 75mg/m2 IV over 30min daily on days 1-7. This dose is the same for all dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Dose level 1 Velcade 0.7mg/m2 IVP on days 2 and 5 Dose level 2 Velcade 0.7mg/m2 IVP on days 2, 5, 9, 12 Dose level 3 Velcade 1.0 mg/m2 IVP on days 2, 5, 9, 12 Dose level 4 Velcade 1.3 mg/m2 IVP on days 2, 5, 9, 12
Study: NCT01791673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound glaucoma treatment
Description: Ultrasound glaucoma treatment with EYEOP1 device
Study: NCT03226769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrueTear™
Description: Intranasal application of TrueTear™ device for approximately 8 minutes at Day 0, for approximately 3 minutes at Day 7 and then daily use of TrueTear™ per participant guide.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermalon Dry Eye Compress
Description: Application of Thermalon Dry Eye Compress at Day 0, Day 7 and daily use as per label instructions.
Study: NCT04007120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-1601
Description: Inhaled RVT-1601 administered once daily over two days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-1601
Description: Inhaled RVT-1601 administered once daily over two days
Study: NCT02307279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelesis100

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02065336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520
Study: NCT01211769

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A pill with 50mg of talcum powder, identical to the pill of naltrexone; associated to PUFAs Placebo pills (yellow liquid paraffin identical to the pills of borage seed and fish oil).

Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone + Placebo
Description: A pill of naltrexone chlorhydrate 50mg, associated to Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs.
Study: NCT01439503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention will consist of an education program. The education program includes providing the ability to enjoy condom use through improved skills related to finding the right fit and feel of condoms, using lubricants that are compatible with latex, negotiating condom use, negotiating sex, and talking with new and existing sex partners about ways to sexualize condoms.
Study: NCT01271764

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: no drug
Description: The role of G9a protein in patients with endometrial cancer
Study: NCT02065336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: entecavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Study: NCT01890798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drisapersen
Description: Drisapersen will be supplied as 3 millilitre (mL) vials containing 1mL sterile solution for subcutaneous injection. The strength of drisapersen solution will be 200 mg/mL.
Study: NCT01689285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valacyclovir tablet
Description: 16 healthy adult volunteers (18-55 yr) will be exposed to one tablet
Study: NCT01877538

Intervention type: OTHER
Intervention: [11C]donepezil PET
Description: Positron Emission Tomography (PET) imaging of acetylcholinesterase with the ligand \[11C\]donepezil
Study: NCT02125201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: A neonate will recieve Fentanyl intranasal or intravenous 5 minutes before the procedure The nurse will check his pain scale If the pain scale will be more than 4 the neonate will recieve the second dose of Fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: A neonate will recieve Fentanyl intranasal or intravenous 5 minutes before the procedure The nurse will check his pain scale If the pain scale will be more than 4 the neonate will recieve the second dose of Fentanyl
Study: NCT03886532

Intervention type: OTHER
Intervention: Medical Marijuana
Description: registry and blood samples

Intervention type: OTHER
Intervention: Medical Marijuana
Description: registry and blood samples
Study: NCT02432261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nestorone® /testosterone gel
Description: Nestorone® /testosterone combined gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone only gel
Description: Testosterone only gel
Study: NCT00210626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROCRIT
Description: 40,000 IU/mL/week for max of 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40,000 IU/mL/week for max of 12 weeks
Study: NCT00969839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovaLign Intramedullary Fixation System
Description: Intramedullary fixation of broken humerus
Study: NCT03238768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Intravenous Nutrition
Description: Increased macronutrients for first 7 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Intravenous Nutrition
Description: Standard macronutrients for first 7 days
Study: NCT01215123

Intervention type: DRUG
Intervention: Bevacizumab
Description: Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.
Study: NCT04449159

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vinh Wellness Collagen
Description: Vinh Wellness Collagen is hydrolyzed collagen

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01885637

Intervention type: OTHER
Group type: OTHER
Intervention: Transition program
Description: Accelerated transition program from oncological treatment to continuous specialized palliative care and psychological intervention at home for incurable cancer patients
Study: NCT03377556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study: NCT03474341

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: * Anatomical (T2W) and functional MRI (DWI and DCE) at a 1.5T Siemens or Philips scanner~* DWI series: sagittal (sIVIM) and high-resolution transversal (HR tDWI)~* DCE serie: dynamic20~* In total, three MRI scan series (before, during, after nCRT)~* Measurements: i.a. change in apparent diffusion coefficient (ADC) or area-under-the-gadolinium-concentration time curve (AUC) within tumor delineation over time, radiological (qualitative) assessment of residual disease

Intervention type: DIAGNOSTIC_TEST
Intervention: PET-CT
Description: * According to European Association of Nuclear Medicine (EANM) Research Ltd guidelines (EARL)~* In total one additional PET-CT (during nCRT) for study purposes. A PET-CT scan at diagnosis and after nCRT are included in the standard diagnostic work-up for esophageal cancer.~* Measurements: i.a. change in TLG (Total Lesion Glycolysis), SUVmax (Standardized Uptake Value) or Ktrans within tumor delineation over time
Study: NCT00544583

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted sutures
Description: Interrupted sutures for abdominal fascia closure with Vicryl equivalent sutures (USP 2, 45 cm)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous sutures
Description: Continuous sutures for abdominal fascia closure with PDS II equivalent USP 1, 150 cm loops
Study: NCT01689285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir oral solution
Description: 16 healthy adult volunteers (18-55 yr) will be exposed to 10 ml once
Study: NCT01092988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate 2100
Description: MR guided focused ultrasound
Study: NCT03856814

Intervention type: DEVICE
Intervention: ELVeS® Radial® 2ring slim fiber used for EndoVenous Laser Ablation
Description: Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
Study: NCT04934878

Intervention type: BIOLOGICAL
Intervention: Referral information
Description: first visit to our hospital/transfer from another hospital
Study: NCT03474341

Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopy
Description: Additional endoscopy and/or endoscopic ultrasonography (EUS) with biopsies of the primary tumor site and other suspected lesions in the esophagus after completion of nCRT and prior to surgery
Study: NCT03235401

Intervention type: OTHER
Intervention: 37-items questionnaire
Description: Patient will answer the PAH-DBoQ questionnaire